Sarah Louden: Building educational programs about the transformative power of AI in cancer care
Douglas Flora shared a post by on LinkedIn:
“My Tensor Black partners and I are very excited to work with this talented group from Total Health | Oncology doing what they do best—offering oncologists important and practical education that helps us take better care of our patients.
AI has the potential to revolutionize oncology care in countless ways. It can improve clinical trial screening and enrollment, enhance early detection through better imaging and diagnostics, and personalize treatment with greater precision. Additionally, AI can assist in drug discovery, optimize resource management, predict patient outcomes, and significantly reduce administrative burdens like documentation. By responsibly deploying AI, we can transform patient care, making our work more efficient and impactful.
We’re committed to ensuring that oncologists are equipped with the tools and knowledge they need to harness AI’s full potential, driving better outcomes for patients everywhere. Let us know if you’d like to be involved in any way.
Thank you, Total Health | Oncology, Sarah Louden, Maureen Schnepf, and Kayla Baylock for your talent and vision—I am proud to count you as friends and partners in this important work. ”
Quoting ‘s post:
“Exciting times ahead as I help some amazing friends launch a new initiative centered around AI in oncology. We’re building educational programs that will showcase the transformative power of AI in cancer care, and we’re on the lookout for sponsors and speakers to join us on this journey. If you’re passionate about the future of oncology, let’s connect and collaborate!”
Source: Douglas Flora/LinkedIn and
Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, overseeing clinical operations, strategic planning, and the expansion of cancer programs. He is also the co-founder of the Center for Precision Medicine; Genomic Health.
As the Editor-in-Chief of ‘AI in Precision Oncology,’ the first peer-reviewed academic journal dedicated to this field, he plays a pivotal role in advancing research. He is also an active board member of the American Cancer Society and ACCC, where he contributes to advocacy, education, and innovation within the cancer community.